| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EOLS | Common Stock | Award | $0 | +23.8K | +6.49% | $0.00 | 390K | Mar 7, 2025 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EOLS | Performance Restricted Stock Units | Award | $0 | +23.8K | $0.00 | 23.8K | Mar 7, 2025 | Common Stock | 23.8K | Direct | F2, F3 | ||
| transaction | EOLS | Stock Option (Right to Buy) | Award | $0 | +33.9K | $0.00 | 33.9K | Mar 7, 2025 | Common Stock | 33.9K | $13.58 | Direct | F4 |
| Id | Content |
|---|---|
| F1 | Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of March 7, 2025, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. |
| F2 | Each performance-based restricted stock unit (PSU) represents the right to receive, following vesting, a number of shares of common stock of the issuer up to 200% of the number of PSUs. |
| F3 | The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 100% of the PSUs will vest on March 7, 2028 in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates. |
| F4 | The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of March 7, 2025, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. |
Chief Medical Officer and Head of R&D